Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS6 | Q8IU80 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HPN | P05981 | 3/20 | 0.45 |
| ▸ | PLAU | P00749 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458574 | 0.84 | CA2 (0.53) | ALDH1A1MAPTSMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL14448891 | 0.80 | TMPRSS6 (0.60) | TMPRSS6ALDH1A1SMN1; SMN2F2PRSS1 | |
| SCHEMBL3716571 | 0.79 | ALDH1A1 (0.54) | ALDH1A1MAPTSMN1; SMN2F2PRSS1 | |
| SCHEMBL3643243 | 0.79 | ALDH1A1 (0.58) | ALDH1A1MAPTSMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL2408403 | 0.76 | ALDH1A1 (0.59) | ALDH1A1MAPTSMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL1479992 | 0.76 | ALDH1A1 (0.59) | ALDH1A1MAPTSMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL12348122 | 0.75 | TMPRSS6 (0.58) | TMPRSS6ALDH1A1F2PRSS1PRSS2 | |
| SCHEMBL8486571 | 0.75 | ALDH1A1 (0.64) | ALDH1A1MAPTSMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL7895365 | 0.75 | MEN1 (0.54) | ALDH1A1MAPTSMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL8724306 | 0.75 | ALDH1A1 (0.50) | ALDH1A1MAPTSMN1; SMN2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-117836270-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4305021-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192562-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-6114328-A | ANTICOAGULANTS; BLOOD DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-09-05 | — | — | US | disclosed |
| US-5849736-A | Isoxazoline and isoxazole fibrinogen receptor antagonists | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0730590-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | TMPRSS6 2305/4885ALDH1A1 2021/4885MAPT 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.